Comparison of Radiomic Models Based on Low-Dose and Standard-Dose CT for Prediction of Adenocarcinomas and Benign Lesions in Solid Pulmonary Nodules

Jieke Liu†, Hao Xu†, Haomiao Qing, Yong Li, Xi Yang, Changjiu He, Jing Ren and Peng Zhou*

Department of Radiology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

Objectives: This study aimed to develop radiomic models based on low-dose CT (LDCT) and standard-dose CT to distinguish adenocarcinomas from benign lesions in patients with solid solitary pulmonary nodules and compare the performance among these radiomic models and Lung CT Screening Reporting and Data System (Lung-RADS). The reproducibility of radiomic features between LDCT and standard-dose CT were also evaluated.

Methods: A total of 141 consecutive pathologically confirmed solid solitary pulmonary nodules were enrolled including 50 adenocarcinomas and 48 benign nodules in primary cohort and 22 adenocarcinomas and 21 benign nodules in validation cohort. LDCT and standard-dose CT scans were conducted using same acquisition parameters and reconstruction method except for radiation dose. All nodules were automatically segmented and 104 original radiomic features were extracted. The concordance correlation coefficient was used to quantify reproducibility of radiomic features between LDCT and standard-dose CT. Radiomic features were selected to build radiomic signature, and clinical characteristics and radiomic signature were combined to develop radiomic nomogram for LDCT and standard-dose CT, respectively. The performance of radiomic models and Lung-RADS was assessed by area under curve (AUC) of receiver operating characteristic curve, sensitivity, and specificity.

Results: Shape and first order features, and neighboring gray tone difference matrix features were highly reproducible between LDCT and standard-dose CT. No significant differences of AUCs were found among radiomic signature and nomogram of LDCT and standard-dose CT in both primary and validation cohort (0.915 vs. 0.919 vs. 0.898 vs. 0.909 and 0.976 vs. 0.976 vs. 0.985 vs. 0.987, respectively). These radiomic models had higher specificity than Lung-RADS (all correct P < 0.05), while there were no significant differences of sensitivity between Lung-RADS and radiomic models.
INTRODUCTION

Lung cancer is the leading cause of cancer-related death worldwide (1–3). Low-dose computed tomography (LDCT) has been widely recommended for lung cancer screening as it can reduce the mortality (4, 5), but concerns about the high false-positive rate of diagnosis and the following overtreatment are also emerging (4, 6–8). Radiomics, via high-throughput extraction of features from imaging data, has been applied to risk prediction, diagnostic discrimination, and disease progression, and improves decision-making in oncology (9–11). In recent years, a large number of studies build radiomic models using either LDCT (12–17) or standard-dose CT data (18–20) to predict malignancy of solitary pulmonary nodules, however, one key question that remains unanswered is whether the performance of LDCT-based radiomic model and underlying significant features are equivalent to that of standard-dose CT.

Concurrent with the recent prosperities on radiomics, the effect of scan acquisition parameters on the reproducibility of quantitative radiomic features aroused concerns of researchers. Studies in phantom and in vivo demonstrated that scanner variability, radiation dose, reconstruction method, and slice thickness did affect the quantification of many radiomic features (21–25). Therefore, the LDCT-based radiomic model may be not identical to that of standard-dose CT due to radiation dose reduction even though the other acquisition parameters are consistent. To study the effect of radiation dose reduction on radiomic features in vivo, Lo et al. applied the noise addition methods to simulate dose reduction conditions (22), while Solomon et al. repeated scan with half standard dose (23). Their results indicated some texture features were not reproducible when reducing radiation dose. However, the reproducibility of radiomic features of solitary pulmonary nodules between LDCT for lung cancer screening and standard-dose CT examinations remains unaddressed.

Adenocarcinoma is the most prevalent histologic type of lung cancer (26, 27), making it the most common true-positive finding in lung cancer screening (4, 5). Granulomas often appear as spiculated or lobulated solid nodules and are fluorodeoxyglucose avid, and therefore mimic invasive adenocarcinomas, representing the most confounding false-positive findings in lung cancer screening (4, 28). Many investigators attempted to distinguish granulomas from adenocarcinomas using radiomic features (29–33), but none of them used low-dose acquisition parameters. Besides, the radiomic model without including non-specific inflammation, hamartoma, and other benign lesions might limit its utility in lung cancer screening.

Conclusions: The diagnostic performance of LDCT-based radiomic models to differentiate adenocarcinomas from benign lesions in solid pulmonary nodules were equivalent to that of standard-dose CT. The LDCT-based radiomic model with higher specificity and lower false-positive rate than Lung-RADS might help reduce overdiagnosis and overtreatment of solid pulmonary nodules in lung cancer screening.

Keywords: radiomics, low-dose computed tomography, lung cancer screening, lung adenocarcinoma, benign lesion, solid pulmonary nodule

MATERIALS AND METHODS

Pulmonary Nodules

This study was approved by the Institutional Review Board and the requirement for informed consent was waived as the data were analyzed retrospectively and anonymously.

A total of 141 solid solitary pulmonary nodules (72 adenocarcinomas and 69 benign nodules) were consecutively included in this study from April 2019 and May 2020, according to the following inclusion criteria: 1) detection of solid solitary pulmonary nodule without calcification for typical benign lesion; 2) LDCT obtained from lung cancer screening; 3) standard-dose CT obtained within 24 h after LDCT to evaluate hilar and mediastinal lymph nodes; 4) pathologically confirmed. The exclusion criteria were as follows: 1) history of cancer in previous 5 years; 2) images of poor quality with respiratory and movement artifacts; 3) nodules with undefined border resulting in poor segmentation.

We divided the nodules into two independent cohorts according to a ratio of 7:3 and the date of inclusion. Fifty adenocarcinomas and 48 benign nodules enrolled between April 2019 and November 2019 constituted the primary cohort, and 22 adenocarcinomas and 21 benign nodules enrolled between November 2019 and May 2020 constituted the validation cohort. The radiologist (HQ, with 7 years of experience in thoracic radiology) who was blinded to the final diagnosis performed categorization on nodules according to Lung-RADS (34).

Image Acquisition

All LDCT and standard-dose CT scans were performed on a 256-slice multi-detector CT scanner (Brilliance iCT, Philips Healthcare, Amsterdam, Netherlands), using the following acquisition parameters: tube voltage of 100 kV and tube current of 20 or 30 mAs for LDCT, tube voltage of 120 kV and...
tube current of 100 to 250 mAs for standard-dose CT, standard resolution mode, detector collimation of 128 × 0.625 mm, helical pitch of 0.915, and gantry rotation time of 0.4 s. All the raw datasets were then reconstructed using the hybrid iterative reconstruction method (iDose4, level 6, Philips Healthcare, Amsterdam, Netherlands) with standard reconstruction filter for body, slice thickness of 0.625 mm, slice increment of 0.625 mm, field of view of 350 mm × 350 mm, and matrix of 1,024 × 1,024. The estimated effective dose of LDCT scan for all subjects was 0.68 ± 0.11 mSv (range from 0.40 to 0.93).

Segmentation and Radiomic Features Extraction
All target nodules were automatically detected and segmented using uAI platform (United Imaging Healthcare, Shanghai, China), an artificial intelligence software basing on deep learning method (35, 36). No manual adjustments of the segmentation results were performed to avoid inter-observer and intra-observer variability. The representative segmentation results were shown in Figure 1. A total of 104 original radiomic features, including first order, shape, and texture features, were extracted from the target nodules using an open-source Python package (PyRadiomics, version 3.0, https://pyradiomics.readthedocs.io) (37). Further details of radiomic features are provided in the Supplementary Material.

Quantifying Feature Reproducibility
The concordance correlation coefficient (CCC) was used to quantify reproducibility of extracted radiomic features between LDCT and standard-dose CT in the combined primary and validation cohorts (38). A radiomic feature with CCC ≥ 0.90 was then defined as a reproducible feature, as previously described (39–41). The percentage of features in each category with a CCC of ≥0.85, ≥0.90, and ≥0.95 was calculated, respectively.

Feature Selection and Radiomic Signature Construction
Features were standardized using z-score normalization and then selected to build radiomic signature in the primary cohort of LDCT and standard-dose CT dataset respectively. Firstly, the Mann-Whitney U test was employed to select the features that were statistically different between groups (unadjusted \( P < 0.05 \)), as the quantitative radiomic features did not have a normal distribution. Secondly, Spearman correlation analysis and minimum redundancy-maximum relevance (mRMR) (42) were sequentially conducted to exclude redundant radiomic features. Highly correlated features (Spearman correlation coefficient >0.9) were excluded and the top ranked 10 features were reserved. Thirdly, the least absolute shrinkage and selection operator (LASSO) method was used to select the most predictive features from the primary cohort (43). Finally, multivariate logistic regression with backward stepwise selection was applied to construct radiomic score (Rad-score), in which the stopping rule was the likelihood ratio test with Akaike’s information criterion (44). Rad-score of each patient in was calculated via a linear combination of the selected features and weighted by the respective coefficients.

Radiomic Nomogram Construction
Independent factors for differentiating adenocarcinomas from benign nodules among Rad-score and clinical variables were identified by inputting significant variables found using univariate logistic regression analysis. Multivariable logistic regression analysis was applied to build radiomic nomogram for LDCT and standard-dose CT respectively, which was a visualized and individual tool that integrated independent factors to predict the probability of adenocarcinoma in the primary cohort.

Performance of Radiomic Signature and Nomogram
The area under the curve (AUC) of receiver operating characteristic (ROC) curve was determined to evaluate the discrimination performance of the radiomic signature and radiomic nomogram of LDCT and standard-dose CT in both primary and validation cohorts. The sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were also calculated. To evaluate the calibration performance of radiomic nomogram, calibration curves were plotted. The Hosmer-Lemeshow (H-L) test was performed to assess the goodness-of-fit of radiomic nomogram.

Clinical Utility
Decision curve analyses were conducted to estimate the clinical utility of the radiomic models and Lung-RADS by calculating the net benefits at a range of threshold probabilities in the combined primary and validation cohorts (45).

Statistical Analysis
Statistical analysis was performed by R software (version 4.0.0, http://www.r-project.org), SPSS software (version 19.0, https://www.ibm.com), and MedCalc (v. 18.21, https://www.medcalc.org). The chi-squared test was used to compare the differences in gender, and group comparisons of age was performed using independent sample t-test. \( P < 0.05 \) was considered statistically significant.

The performance of Lung-RADS was also evaluated. The ROC of Lung-RADS was performed in both primary and validation cohorts according to that nodules of category 4A, 4B, and 4X were labeled as malignancy while category 2 and 3 as benign nodules. The corresponding sensitivity, specificity, accuracy, PPV, and NPV were calculated. Then comparisons of AUCs among radiomic models and Lung-RADS were performed using the Delong test in the primary and validation cohorts (46). In these pairwise models with significant difference in AUC, further comparisons of sensitivity and specificity were performed using the McNemar test in the combined cohort (47). Analyses were corrected for multiple comparisons using the false discovery rate (FDR) method (48).
RESULTS

Clinical Characteristics

The baseline clinical-pathologic characteristics, including gender, age, Lung-RADS category, and histologic subtype of benign nodules in the primary and validation cohorts are listed in Table 1. There was no difference in gender between the adenocarcinoma group and the benign group in the primary or validation cohorts. Significant differences were found in age between the two groups in primary and validation cohorts ($P = 0.003$ and $P < 0.0001$, respectively).

Feature Reproducibility

The reproducibility of radiomic features between LDCT and standard-dose CT regarding different feature categories is
presented in the Supplementary Material. Shape and neighboring gray tone difference matrix (NGTDM) features were most reproducible (100%), followed by first order features (n = 16/18, 89%). Besides, 57% gray-level cooccurrence matrix (GLCM, n = 12/21), 50% gray level size zone matrix (GLSZM, n = 8/16), and 43% gray level dependence matrix (GLDM, n = 6/14) features were reproducible. Gray-level run length matrix (GLRLM) features were least reproducible (n = 5/16, 31%).

Feature Selection and Radiomic Signature Construction
The process of feature selection is presented in the Supplementary Material. Finally, three features in LDCT (GLCM_DifferenceVariance, GLRLM_RunEntropy, and NGTDM_Strength) and two features in standard-dose CT (GLSZM_ZoneEntropy and NGTDM_Strength) were selected in the primary cohort. The representative maps of these texture feature were shown in Figure 1. The calculation formulas of Rad-score basing on these features with nonzero coefficients are presented in the Supplementary Material.

Radiomic Nomogram Construction
According to univariate logistic regression analysis, age, Rad_score of LDCT, and Rad_score of standard-dose CT were significant independent differentiators of adenocarcinomas and benign nodules (Table 2), and they were integrated to develop the radiomic nomograms for predicting the probability of adenocarcinoma of LDCT and standard-dose CT respectively (Figures 2A, B). The calculation formulas of radiomic nomogram are presented in the Supplementary Material.

Performance of Radiomic Signature, Radiomic Nomogram, and Lung-RADS
The ROC curves of radiomic models and Lung-RADS are shown in Figure 3. The AUC, sensitivity, specificity, accuracy, PPV, and NPV of each model are shown in Table 3.

The calibration curves of the radiomics nomogram of LDCT and standard-dose CT for the probability of adenocarcinoma demonstrated good agreement between prediction and observation in the primary and validation cohorts (Figures 2C, D). The H-L test yielded non-significant results in the both primary and validation cohorts of LDCT (P = 0.650 and 0.998) and standard-

### Table 1: Characteristics of adenocarcinomas and benign nodules in the primary and validation cohorts.

| Characteristic               | Primary cohort (n = 98) | Validation cohort (n = 43) | P     |
|-----------------------------|-------------------------|---------------------------|-------|
|                             | Adenocarcinoma (n = 50) | Benign (n = 48)           |       |
|                             |                         |                           |       |
| Gender                      | 0.69                    |                           |       |
| Female                      | 22                      | 19                        |       |
| Male                        | 28                      | 29                        |       |
| Age (years)                 | 61.32 ± 1.30            | 53.96 ± 1.44              | 0.0003|
| Lung-RADS category          |                         |                           |       |
| 2, 3                        | 2                       | 27                        |       |
| 4A, 4B, 4X                  | 48                      | 21                        |       |
| Histologic subtype          |                         |                           |       |
| Inflammation                | 17                      | 10                        |       |
| Granulomas                  | 17                      | 7                         |       |
| Hamartoma                   | 6                       | 1                         |       |
| PSP                         | 5                       | 0                         |       |
| Other benign entities       | 3                       | 3                         |       |

Age is shown in means ± standard deviation, and the other data are the number of nodules. Granulomas are caused by Mycobacterium tuberculosis, Cryptococcus neoformans, and other unspecified conditions. Other benign entities include intrapulmonary lymph node, fibroplasia, and lymphoid hyperplasia. Lung-RADS, Lung CT Screening Reporting and Data System; PSP, pulmonary sclerosing pneumocytoma.

### Table 2: Univariate and multivariate logistic regression analysis of factors for differentiating adenocarcinomas from benign nodules in the primary cohort.

| Variables                        | Odds ratio | 95% confidence interval | P     |
|----------------------------------|------------|-------------------------|-------|
| Univariate logistic regression   |            |                         |       |
| Age                              | 1.085      | 1.035–1.137             | 0.0008|
| Gender                           | 1.199      | 0.537–2.680             | 0.658 |
| Rad_score of low-dose CT         | 2.718      | 1.718–4.302             | <0.0001|
| Rad_score of standard-dose CT    | 2.718      | 1.785–4.410             | <0.0001|
| Multivariate logistic regression |            |                         |       |
| Low-dose CT                      | Rad_score  | 2.601                   | <0.0001|
|                                  | Age        | 1.052                   | 0.990–1.117 | 0.104 |
| Standard-dose CT                 | Rad_score  | 2.638                   | 1.713–4.061 | 0.088 |
|                                  | Age        | 1.053                   | 0.992–1.118 | <0.0001|

Rad_score, radiomic score.
dose CT ($P = 0.151$ and $0.988$), which suggested no departure from a perfect fit.

According to the DeLong test, the AUCs of the radiomic models were higher than that of Lung-RADS in the primary and validation cohorts (all correct $P < 0.05$), while there were no significant differences among the radiomic models (Table 4). The McNemar test results further showed the radiomic models had higher specificity than Lung-RADS in the combined cohort (all correct $P < 0.05$), while there were no significant differences of sensitivity between Lung-RADS and radiomic models (Table 5).

**Clinical Utility**
The results of decision curve analyses for the radiomic models and Lung-RADS are presented in Figure 4. The decision curves showed that the model of radiomic signature of low-dose CT, radiomic nomogram of low-dose CT, radiomic signature of standard-dose CT, and radiomic nomogram of standard-dose CT added more net benefit than Lung-RADS in differentiating adenocarcinomas from benign nodules within the range of the threshold probability of 0.02 to 0.84, 0.02 to 0.85, 0.02 to 0.74, and 0.02 to 0.79, respectively.

**DISCUSSION**
In the present study, we investigated the ability of radiomic models based on LDCT and standard-dose CT to distinguish adenocarcinomas from benign lesions in patients with solid solitary pulmonary nodules. We found the AUCs of LDCT-based radiomic models were equivalent to that of standard-dose CT. All the radiomic models showed higher specificity than the Lung-RADS approach, which was consistent with previous report (12, 17). We also assessed the reproducibility of radiomic features of solid solitary pulmonary nodules between LDCT and standard-dose CT examinations in vivo. Generally, shape and first order features were more reproducible than texture features except for NGTDM features.

Radiologists usually stratify pulmonary nodules in lung cancer screening by interpreting characteristics such as location, attenuation, diameter, volume, and margin. The differential diagnosis of solitary solid nodules may be more difficult than that of sub-solid nodules. More than 90% of pathologically confirmed sub-solid nodules were malignant in China (49), while the malignancy rate of solid nodules was 66.6% in previous study (50) and 51.1% in our study. Several possible reasons may lead to the overtreatment of solid nodules in China. First, with high tuberculosis incidence in this country, indeterminate solid nodules caused by granulomas or other inflammations were usually larger than 8 mm with irregular shape and border. These benign nodules had overlapping characteristics with adenocarcinomas in location, size, and morphology (51–53). Thus, the Lung-RADS categorization of these benign nodules were equal to or beyond 4A, resulting in low specificity. The radiomic models developed in this study had higher specificity and lower false-positive rate in distinguishing adenocarcinomas from benign lesions than the Lung-RADS, and they might help clinicians avoid choosing too aggressive approach. Second, 41 of 69 benign nodules in this study were categorized as Lung-RADS 2 or 3, and they were all pathologically confirmed by surgery. The result indicated the great fear of missing malignant
nodules for both patients and surgeons in China, especially in the cancer hospital. Because the medical environment of China tends to favor cautiousness from both patients and clinicians (54).

This study also addressed a very important question that radiomic models based on LDCT and standard-dose CT had equivalent diagnostic performance to differentiate adenocarcinomas from benign lesions in solid nodules. NGTDM_Strength was highly reproducible and thus the common significant texture feature related to benign nodules in both LDCT and standard-dose CT models. Higher value of NGTDM_Strength indicates an image with slower change in intensity but larger coarse differences in gray level intensities. It suggested benign nodules were more homogeneous than adenocarcinomas. Besides, the other significant texture features related to adenocarcinomas included GLCM_DifferenceVariance and GLRLM_RunEntropy in LDCT model and GLSZM_Zone Entropy in standard-dose CT model. They all indicated that

**FIGURE 3** | Receiver operating characteristic (ROC) curves of the radiomic models and Lung CT Screening Reporting and Data System (Lung-RADS) for differentiating adenocarcinomas from benign nodules. (A) Primary cohort. (B) Validation cohort.

**TABLE 3 |** Diagnostic performance the radiomic signature and radiomic nomogram of low-dose CT and standard-dose CT, and Lung-RADS for differentiating adenocarcinomas from benign nodules in the primary and validation cohorts.

|                          | AUC (95% CI) | Sensitivity | Specificity | Accuracy | PPV   | NPV   |
|--------------------------|--------------|-------------|-------------|----------|-------|-------|
| **Primary cohort**       |              |             |             |          |       |       |
| Radiomic signature       | 0.915        | 0.860       | 0.854       | 0.857    | 0.860 | 0.854 |
| of low-dose CT           | (0.859–0.972)| (43/50)     | (41/48)     | (84/98)  | (43/50)| (41/48)|
| Radiomic signature       | 0.919        | 0.920       | 0.854       | 0.888    | 0.888 | 0.911 |
| of low-dose CT           | (0.861–0.977)| (46/50)     | (41/48)     | (87/98)  | (46/53)| (41/45)|
| Radiomic signature       | 0.898        | 0.940       | 0.792       | 0.867    | 0.825 | 0.927 |
| of standard-dose CT      | (0.833–0.963)| (38/48)     | (38/48)     | (85/98)  | (47/57)| (38/41)|
| Radiomic signature       | 0.909        | 0.840       | 0.896       | 0.867    | 0.894 | 0.843 |
| of standard-dose CT      | (0.946–0.972)| (43/48)     | (43/48)     | (85/98)  | (42/47)| (43/51)|
| Lung-RADS                | 0.761        | 0.960       | 0.562       | 0.765    | 0.696 | 0.931 |
|                          | (0.685–0.837)| (48/50)     | (27/48)     | (75/98)  | (48/69)| (27/29)|
| **Validation cohort**    |              |             |             |          |       |       |
| Radiomic signature       | 0.976        | 0.884       | 0.857       | 0.860    | 0.864 | 0.857 |
| of low-dose CT           | (0.944–1.000)| (19/22)     | (19/21)     | (37/43)  | (19/22)| (18/21)|
| Radiomic signature       | 0.976        | 0.909       | 0.905       | 0.907    | 0.909 | 0.905 |
| of low-dose CT           | (0.941–1.000)| (20/22)     | (19/21)     | (39/43)  | (20/22)| (19/21)|
| Radiomic signature       | 0.985        | 0.955       | 0.905       | 0.930    | 0.913 | 0.950 |
| of standard-dose CT      | (0.960–1.000)| (21/22)     | (19/21)     | (40/43)  | (21/23)| (19/20)|
| Radiomic signature       | 0.987        | 0.909       | 0.952       | 0.930    | 0.952 | 0.909 |
| of standard-dose CT      | (0.965–1.000)| (20/22)     | (20/21)     | (40/43)  | (20/21)| (20/22)|
| Lung-RADS                | 0.833        | 1.000       | 0.667       | 0.837    | 0.759 | 1.000 |
|                          | (0.730–0.937)| (22/22)     | (14/21)     | (36/43)  | (22/29)| (14/14)|

Unless otherwise specified, numbers in the parentheses were used to calculate percentages. Lung-RADS, Lung CT Screening Reporting and Data System; AUC, area under curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.
adenocarcinomas had more heterogeneity than benign nodules in the texture patterns. The shape and first order features, representing the morphology and attenuation characteristics, were highly reproducible as radiation dose changed. However, they were not included in LDCT or standard-dose CT models, suggesting the deficiency of traditional image features to stratify the indeterminate solid nodules.

We acknowledged several limitations in this study. First, this was a single-center retrospective study with relatively small sample size. The advantage was the standardization of acquisition parameters, avoiding potential confounding variability caused by heterogeneous parameters and image preprocessing (21, 25). Further multi-center study with larger datasets is needed to validate the reported radiomic models. Second, only pathologically confirmed nodules

| Pairwise comparison                                      | Primary cohort                  | Validation cohort                  |
|----------------------------------------------------------|---------------------------------|-----------------------------------|
|                                                          | Z     | P                     | Z     | P                     |
| Lung-RADS vs. Radiomic signature of low-dose CT          | 4.012 | 0.0001*               | 2.643 | 0.0082*               |
| Lung-RADS vs. Radiomic nomogram of low-dose CT          | 4.123 | <0.0001*              | 2.679 | 0.0074*               |
| Lung-RADS vs. Radiomic signature of standard-dose CT    | 3.329 | 0.0009*               | 2.732 | 0.0063*               |
| Lung-RADS vs. Radiomic nomogram of standard-dose CT     | 3.713 | 0.0002*               | 2.798 | 0.0051*               |
| Radiomic signature of low-dose CT vs. Radiomic nomogram of low-dose CT | 0.354 | 0.7236            | <0.001 | 0.999            |
| Radiomic signature of low-dose CT vs. Radiomic signature of standard-dose CT | 1.058 | 0.2903          | 0.707 | 0.4794          |
| Radiomic signature of low-dose CT vs. Radiomic nomogram of standard-dose CT | 0.385 | 0.7003          | 0.928 | 0.3534          |
| Radiomic nomogram of low-dose CT vs. Radiomic signature of standard-dose CT | 1.037 | 0.2998          | 0.599 | 0.5492          |
| Radiomic nomogram of low-dose CT vs. Radiomic nomogram of standard-dose CT | 0.663 | 0.5075          | 0.841 | 0.4003          |
| Radiomic signature of standard-dose CT vs. Radiomic nomogram of standard-dose CT | 1.019 | 0.3084          | 0.402 | 0.6877          |

*Differences are significant at P < 0.05 corrected with false discovery rate. Lung-RADS, Lung CT Screening Reporting and Data System.

| Pairwise comparison                                      | Sensitivity   | Specificity   |
|----------------------------------------------------------|---------------|---------------|
|                                                          | X²             | P             | X²             | P             |
| Lung-RADS vs. Radiomic signature of low-dose CT          | 4.900         | 0.0269        | 12.042         | 0.0005*       |
| Lung-RADS vs. Radiomic nomogram of low-dose CT          | 0.167         | 0.6831        | 9.375          | 0.0022*       |
| Lung-RADS vs. Radiomic signature of standard-dose CT    | 1.500         | 0.2207        | 14.087         | 0.0002*       |
| Lung-RADS vs. Radiomic nomogram of standard-dose CT     | 4.900         | 0.0269        | 16.962         | <0.0001*      |

*Differences are significant at P < 0.05 corrected with false discovery rate. Lung-RADS, Lung CT Screening Reporting and Data System.

FIGURE 4 | Decision curves of the radiomic models and Lung CT Screening Reporting and Data System (Lung-RADS). The decision curves showed that the model of radiomic signature of low-dose CT, radiomic nomogram of low-dose CT, radiomic signature of standard-dose CT, and radiomic nomogram of standard-dose CT added more net benefit than Lung-RADS in differentiating adenocarcinomas from benign nodules within the range of the threshold probability of 0.02 to 0.84, 0.02 to 0.85, 0.02 to 0.74, and 0.02 to 0.79, respectively.
were enrolled and nodules with undefined border resulting in poor segmentation were excluded, leading to potential selection bias. Third, nodule segmentation was performed with an artificial intelligence software basing on deep learning method and the underlying parameters were inherently in black box. The advantage of automatic segmentation method was high reproducibility, avoiding inter-observer and intra-observer variability that resulting from manual segmentation.

In conclusion, the diagnostic performance of radiomic models based on LDCT and standard-dose CT to differentiate adenocarcinomas from benign lesions in solid pulmonary nodules were equivalent. These radiomic models had higher specificity and lower false-positive rate than Lung-RADS. The LDCT-based radiomic model might be an effective tool for reducing overdiagnosis and overtreatment of solid pulmonary nodules in lung cancer screening.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Ethics Review Board of Sichuan Cancer Hospital and Technology of China. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS
JL, JR, and PZ conceived and designed the study. HQ, YL, XY, and CH collected the data. JL and HX analyzed the data and drafted the manuscript. All authors reviewed the manuscript and PZ revised the final manuscript. HQ and PZ provided funding for the study. All authors contributed to the article and approved the submitted version.

FUNDING
This study was supported by Sichuan Science and Technology Program (grant numbers 2019YJ05085, 2021YFS0075) and Chengdu Science and Technology Program (grant number 2018-YF05-01134-SN).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.634298/full#supplementary-material

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin (2020) 70(1):7–30. doi: 10.3322/caac.21590
2. GBD Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (2018) 392(10159):1736–88. doi: 10.1016/S0140-6736(18)32203-7
3. Gao S, Li N, Wang S, Zhang F, Wei W, Li N, et al. Lung Cancer in People\’s Republic of China. J Thorac Oncol (2020) 15(10):1567–76. doi: 10.1016/j.jtho.2020.04.028
4. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 365(5):395–409. doi: 10.1056/NEJMoa1102873
5. de Koning HI, van der Aalst CM, de Jong PA, Scholten ET, Nakaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med (2020) 382(6):503–13. doi: 10.1056/NEJMoa1911793
6. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA (2012) 307(22):2418–29. doi: 10.1001/jama.2012.5521
7. Veronesi G, Masionneuve P, Bellomi M, Rampinelli C, Durlt I, Bertolotti R, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med (2012) 157(11):776–84. doi: 10.7326/0003-4819-157-11-201210040-00005
8. Patz EJ, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tamemagi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med (2014) 174(2):269–74. doi: 10.1001/jamainternmed.2013.12738
9. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer (2012) 48(4):441–6. doi: 10.1016/j.ejca.2011.11.036
10. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More Than Pictures, They Are Data. Radiology (2016) 278(2):563–77. doi: 10.1148/radiol.2015151169
11. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol (2017) 14(12):749–62. doi: 10.1038/nrclinonc.2017.141
12. Hawkins S, Wang H, Liu Y, Garcia A, Stringfield O, Kremer H, et al. Predicting Malignant Nodules from Screening CT Scans. J Thorac Oncol (2016) 11(12):2120–8. doi: 10.1016/j.jtho.2016.07.002
13. Paul R, Hawkins SH, Schabath MB, Gillies RJ, Hall LO, Goldgof DB. Predicting malignant nodules by fusing deep features with classical radiomics features. J Med Imaging (Bellingham) (2018) 5(1):11021. doi: 10.1117/1.JMI.5.1.11021
14. Choi W, Oh JH, Riyahi S, Liu CJ, Jiang F, Chen W, et al. Radiomics analysis of pulmonary nodules in low-dose CT for early detection of lung cancer. Med Phys (2018) 45(4):1537–49. doi: 10.1002/mp.12820
15. Peikert T, Duan F, Rajagopalan S, Karwoski RA, Smith BJ. Novel high-resolution computed tomography-based radiomic classifier for screen-identified pulmonary nodules in the National Lung Screening Trial. PLoS One (2018) 13(5):e0196910. doi: 10.1371/journal.pone.0196910
16. Delzell DAP, Magnusson S, Peter T, Smith M, Smith BJ. Machine Learning and Feature Selection Methods for Disease Classification With Application to Lung Cancer Screening Image Data. Front Oncol (2019) 9:1393. doi: 10.3389/fonc.2019.01393
17. Mao L, Chen H, Liang M, Li K, Gao J, Qin P, et al. Quantitative radiomic model for predicting malignancy of small solid pulmonary nodules detected by low-dose CT screening. Quant Imaging Med Surg (2019) 9(2):263–72. doi: 10.21037/qims.2019.02.02
18. CH, Chang CK, Tu CY, Liao WC, Wu BR, Chou KT, et al. Radiomic features analysis in computed tomography images of lung nodules classification. PLoS One (2018) 13(2):e0192002. doi: 10.1371/journal.pone.0192002

19. Dimugmarth SR, Padole AM, Rastogi S, Price M, Moordian MJ, Sequist LV, et al. Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT? Cancer Imaging (2019) 19(1):36. doi: 10.1186/s40644-019-0223-7

20. Xu Y, Lu L, E LN, Lian W, Yang H, Schwartz LH, et al. Application of Radiomics in Predicting the Malignancy of Pulmonary Nodules in Different Sizes. A JR Am J Roentgenol (2019) 213(6):1213–20. doi: 10.2214/AJR.19.214190

21. Mackin D, Fave X, Zhang L, Fried D, Yang J, Taylor R, et al. Measuring Computed Tomography Scanner Variability of Radiomics Features. Invest Radiol (2015) 50(11):757–65. doi: 10.1097/RLI.0000000000000180

22. Lo P, Young S, Kim HJ, Brown MS, McNitt-Gray MF. Variability in CT lung-nodule quantification: Effects of dose reduction and reconstruction methods on density and texture based features. Med Phys (2016) 43(8):4854. doi: 10.1118/1.4958485

23. Solomon J, Mileto A, Nelson RC, Roy Choudhury K, Samei E. Quantitative Trends by Histologic Type. Cancer (2014) 120(18):2883–94. doi: 10.1158/1078-0432.ca-14-0764

24. Nakamura H, Saji H. Worldwide trend of increasing primary adenocarcinoma of the lung. J Thorac Dis (2014) 6(3):783–92. doi: 10.1117/1.JMI.5.2.245401

25. Yang X, He J, Wang J, Li W, Liu C, Gao D, et al. CT-based radiomics signature for differentiating solitary granulomatous nodules from solid lung adenocarcinoma. Lung Cancer (2018) 125:109–14. doi: 10.1016/j.lungcan.2018.09.013

26. Beig N, Khorrami M, Alliou M, Rakshit S, Beig N, Khorrami MH, Rajiah P, et al. Perinodular and Intranodular Radiomic Features on Lung CT Images Distinguish Adenocarcinomas from Granulomas. J Med Imaging (Bellingham) (2018) 5(2):24501. doi: 10.1117/1.JMI.5.2.245401

27. American College of Radiology. CT Screening Reporting and Data System (Lung-RADS, Version 1.1) (2019). Available at: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads.

28. Xu DM, van Klaveren RJ, de Bock GH, Leusveld A, Zhao Y, Wang Y, et al. Computational Radiomics System to Decode the Radiographic Phenotype. Cancer Res (2017) 77(21):e104–e7. doi: 10.1158/0008-5472.CAN-17-0339

29. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics (1989) 45(1):255–68. doi: 10.2307/2532051

30. Hunter LA, Kraft S, Stingo F, Choi H, Martel MK, Kyr FF, et al. High quality machine-robust image features: identification in nonsmall cell lung cancer computed tomography images. Med Phys (2013) 40(12):121916. doi: 10.1118/1.4892514

31. Balagurunathan Y, Kumar V, Gu Y, Kim J, Wang H, Liu Y, et al. Test-retest reproducibility analysis of lung CT image features. J Digit Imaging (2014) 27(6):805–23. doi: 10.1002/jdi.34916-x

32. Pan W. Akaike’s information criterion in generalized estimating equations. Biometrics (2001) 57(1):120–5. doi: 10.1111/0006-341x.00120.x

33. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak (2008) 8:53. doi: 10.1186/1472-6947-8-53

34. Delong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 44(3):837–45. doi: 10.2307/2531959

35. Hawass NE. Comparing the sensitivities and specificities of two diagnostic procedures performed on the same group of patients. Br J Radiol (1997) 70(832):360–6. doi: 10.1259/bjr.70.832.9166071

36. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a Practical And Powerful Approach To Multiple Testing. J R Stat Soc Ser B (Methodol) (1995) 57(1):289–300. doi: 10.2307/2346104

37. Yang W, Sun Y, Fang W, Qian F, Ye J, Chen Q, et al. High-resolution Computed Tomography Features Distinguishing Benign and Malignant Lesions Manifesting as Persistent Solitary Subsolid Nodules. Clin Lung Cancer (2018) 19(1):e75–83. doi: 10.1016/j.clincr.2017.05.023

38. She Y, Zhao L, Dai C, Ren Y, Jiang G, Xie H, et al. Development and validation of a nomogram to estimate the pretest probability of cancer in Chinese patients with solid solitary pulmonary nodules: A multi-institutional study. J Surg Oncol (2017) 116(6):756–62. doi: 10.1002/jso.24704

39. Xu DM, van Klaveren RJ, de Boek GH, Leusveld A, Zhao Y, Wang Y, et al. Limited value of shape, margin and CT density in the discrimination between benign and malignant solid nodules of the NELSON trial. Eur J Radiol (2008) 68(2):347–52. doi: 10.1016/j.ejrad.2007.08.027

40. Khan AN, Al-Jahdali HH, Irion KL, Arabi M, Koteyar SS. Solitary pulmonary nodule: A diagnostic algorithm in the light of current imaging technique. Avicenna J Med (2011) 1(2):39–51. doi: 10.4103/2231-0770.90915

41. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midhun DE, Naidich DP, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 143(5 Suppl):e93S–e120S. doi: 10.1378/chest.12-2351
54. Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives. Nat Rev Clin Oncol (2020). doi: 10.1038/s41571-020-00432-6

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.